Jump to content

Ponezumab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DMacks (talk | contribs) at 06:25, 23 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Ponezumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetbeta-amyloid
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6552H10158N1730O2090S52
Molar mass148272.48 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.[1]

Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.[2] Detailed reports have to be released.

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab" (PDF). American Medical Association.
  2. ^ "Alzforum".
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Ponezumab&oldid=964034188"